secwatch.observer — SEC 8-K summary
======================================

Issuer:     Cocrystal Pharma, Inc. (COCP)
CIK:        0001412486
Form:       8-K
Filed at:   2023-12-21T23:59:59+00:00
Accession:  0001493152-23-045742
Event type: other_material
Sentiment:  negative
Materiality: 0.80
Item codes: 1.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Merck terminates influenza A/B collaboration with Cocrystal Pharma; effective March 14, 2024
--------------------------------------------------------------------------------

- Merck terminated Exclusive License and Research Collaboration Agreement for influenza A/B antiviral compounds, effective March 14, 2024.
- Merck cited inability to develop compounds to meet specific program aspect; no existing conditions to continue collaboration.
- Cocrystal received $4M upfront in 2019 and was eligible for milestone payments and royalties—now forfeited.
- Pending patent applications on compounds covered by the Agreement remain in place.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1412486/000149315223045742/0001493152-23-045742-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1412486/000149315223045742/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-23-045742

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer